Asia Practice


The Asia Practice Group at Arnon, Tadmor-Levy has experienced substantial growth over recent years, solidifying its position as one of the leading teams specializing in Asia-Israel transactions in Israel today. Our Asia Practice team actively engages in representing clients in transactions with partners from across Asia including China, Japan, India, Singapore, South Korea, and Azerbaijan.

Our professional connection with Asia-related matters spans diverse industries including infrastructure projects, banking, medical technologies and life sciences, agricultural technologies, and hi-tech. Our transactional experience within the Asia region, particularly in China, is rich and diverse, covering venture capital and private equity transactions, complex commercial IP licensing and joint venture agreements, large-scale infrastructure projects, as well as in-bound and out-bound M&A and capital markets transactions. A highlight for our team was our legal work in connection with the landmark IPO of the first Israeli company to list on the Hong Kong Stock Exchange.

The Asia Practice Group is composed of internationally recognized lawyers with extensive knowledge and experience across the corporate, high technology and life sciences sectors. Our clients place immense value on our lawyers’ legal proficiency, pragmatic approach to problem-solving, and their adept handling of the cultural intricacies that come into play in Asia-Israel transactions.

Our lawyers are frequently invited to speak at conferences and seminars, showcasing their expertise and sharing valuable insights derived from years of practice with Israel-Asia transactions. In addition, we actively build and nurture relationships, regularly welcoming Asian investors and entrepreneurs visiting Israel.

Arnon, Tadmor-Levy has forged strong professional connections with leading law firms throughout Asia. This network positions us to offer our clients comprehensive and tailored legal advice, leveraging the specialized expertise of our international colleagues as needed, including in the areas of corporate, tax and IP matters, as well as international dispute resolution.

Selected Clients & Transactions:

  • The firm acted as Israeli legal counsel in the initial public offering (IPO) of Sisram Medical Ltd, a medical technology company held by Fosun International, for listing on the Hong Kong Stock Exchange led by China International Capital Corporation and Jeffries Hong Kong Limited, the Joint Sponsors. This transaction was the first of its kind and included many complex matters which we handled with the applicable authorities, including obtaining the HKSE’s approval of the State of Israel as an acceptable jurisdiction of incorporation for companies seeking a listing on the HKSE.
  • The firm represented Tencent as the lead investor in a significant equity investment round into Israel’s first digital bank called One Zero, the first Israeli bank to receive a banking license in more than 40 years. One Zero raised up to $120 million from local and international investors led by Tencent together with other large international investors including Swiss bank Julius Baer and Japanese financial group SBI. We recently represented Tencent in a follow-on investment into One Zero.
  • We represented Reshef Technologies Ltd. in connection with a technology transfer and supply agreement valued at tens of millions of dollars with Baharat Electronics of India.
  • The firm represented China Minsheng Financial from Hong Kong in its investment in eToro Group, a leading social trading and multi-asset fintech company.
  • We represented TowerJazz in a transaction with Panasonic Corporation to create a joint venture to manufacture semiconductor products in Japan. The joint venture, which was created and is run through the partnership between TowerJazz and Panasonic Corporation, owns and operates three semiconductor manufacturing facilities located in Uozu, Tonami and Arai, in Hokuriku, Japan.
  • The firm represents BioLineRx, a pipeline drug development company based in Israel. Recently, we represented BioLine in a multimillion-dollar strategic license agreement with China-based Guangzhou Gloria Biosciences Co., Ltd. and an associated investor for the development and commercialization of its lead drug product across all indications in Asia. The transaction also included an equity investment in BioLine.
  • We represented BioModifying LLC in a strategic, multi-million dollar development and licensing transaction with Sun Pharma Advanced Research Company Ltd. of India for the development of treatments for multiple cancer indications.
  • The firm served as Israeli counsel to Shanghai Giant Network Technology in its acquisition of Playtika, a gaming company headquartered in Israel. Shanghai Giant Network Technology led the Chinese consortium that acquired Playtika, which included Alibaba Group founder Jack Ma and his private equity firm Yunfeng Capital, China Oceanwide Holdings Group, China Minsheng Trust, CDH China HF Holdings, and Hony Capital Fund.
  • We represented the State Oil Company of Azerbaijan (SOCAR) in a tender issued by the Israeli Ministry of Energy for offshore exploration licenses. In September of 2023 SOCAR was awarded several licenses and our office is currently representing SOCAR in this process and in their ongoing activities in Israel.
  • The firm represented Takeda Pharmaceutical Company, as part of a consortium, in a successful bid to establish and operate a biotechnological incubator. The incubator was an initiative of the Israel Innovations Authority for the creation and support of pharmaceutical and medical device companies.
  • The firm represents the State Bank of India, one of only five international banks with a license from the Bank of Israel. Recently, we represented the Bank in a multi-million margin loan facility agreement opposite a large publicly traded company in Israel.
  • The firm represents Oramed Pharmaceuticals, a NASDAQ-listed company, that has developed orally ingestible insulin capsules for the treatment of diabetes. We represented Oramed in a multimillion-dollar strategic licensing and manufacturing transaction with Hefei Tianhui Incubator of Technologies Co., Ltd.
  • The firm represented Mitsubishi Electric Corporation in an NIS multi-billion class action, filed against several GIS (Gas Isolated Switchgear) manufacturers and the Israeli Electric Company, on behalf of all consumers of the IEC.
  • We represented Fosun Health Fund (the venture capital arm of Fosun Pharma) in a licensing transaction with Raziel Therapeutics. The parties also signed an exclusive license and supply agreement to develop and commercialize Raziel’s proprietary RZL-012, an injection used for reducing double chins.
  • The firm represented Shanghai Healthcare Capital as lead investor in a multi-million financing round of Biomica Ltd., an Israeli company developing its pipeline of AI-driven microbiome-based therapeutics.
  • The firm represented Honda Europe in connection with new car import regulations and negotiations with its Israeli distributor.
  • We represented Alma Lasers (a subsidiary of Fosun Pharma), a world leader in energy-based medical and aesthetic solutions, in the acquisition of all the assets of PhotonMed International, a leading distributor of energy-based devices in China in one of the largest transactions in which an Israeli company acquired a Chinese company.
  • The firm represented a multinational Indian IT technology service company in establishing a technological development center for companies in the financial sector in Israel.
  • The firm also represents various Japanese companies in their on-going operations in Israel.



Asia Practice- Elite